Protective role of remogliflozin against experimental liver fibrosis by activating AMPK/SIRT1/Nrf2 and suppressing NF-κB pathways

Liver fibrosis is considered an epidemic health problem since it can lead to several insults that can be fatal. Remogliflozin (Remo), an inhibitor of the sodium–glucose cotransporter 2 (SGLT2) protein, is one of the most recently developed antidiabetic drugs for treating type 2 diabetes mellitus (T2...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Frontiers in Pharmacology
المؤلفون الرئيسيون:	Naif ALSuhaymi, Mahdi H. Alsugoor, Aya A. Shokry, Hany M. Fayed, Bassim M. S. A. Mohamed, Sherif M. Afifi, Tuba Esatbeyoglu, Reda M. S. Korany, Marawan A. Elbaset
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Frontiers Media S.A. 2025-06-01
الموضوعات:	liver fibrosis thioacetamide Nrf2 SIRT1 oxidative stress remogliflozin
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1586231/full